MENU
+Compare
LPCN
Stock ticker: NASDAQ
AS OF
Mar 10, 04:58 PM (EDT)
Price
$3.20
Change
-$0.24 (-6.98%)
Capitalization
18.4M

LPCN Lipocine Forecast, Technical & Fundamental Analysis

Lipocine Inc is a clinical-stage biopharmaceutical company... Show more

LPCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for LPCN with price predictions
Mar 04, 2025

Momentum Indicator for LPCN turns negative, indicating new downward trend

LPCN saw its Momentum Indicator move below the 0 level on February 06, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In of the 82 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LPCN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for LPCN entered a downward trend on March 04, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LPCN advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .

LPCN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.962) is normal, around the industry mean (11.742). P/E Ratio (0.000) is within average values for comparable stocks, (66.249). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.790). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (2.315) is also within normal values, averaging (229.516).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. LPCN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LPCN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
LPCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

LPCN is expected to report earnings to rise 962.50% to -42 cents per share on August 09

Lipocine LPCN Stock Earnings Reports
Q2'23
Est.
$-0.43
Q1'23
Missed
by $0.01
Q4'22
Missed
by $0.31
Q3'22
Missed
by $0.48
Q2'22
Missed
by $0.64
The last earnings report on May 11 showed earnings per share of -3 cents, missing the estimate of -2 cents. With 7.94K shares outstanding, the current market capitalization sits at 18.40M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
675 Arapeen Drive
Phone
+1 801 994-7383
Employees
17
Web
https://www.lipocine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X87222.1950001156.515600
+1.34%
Bitcoin cryptocurrency
GME24.30-0.10
-0.41%
GameStop Corp
AAPL235.93-2.10
-0.88%
Apple
SPY576.86-6.91
-1.18%
SPDR® S&P 500® ETF Trust
TSLA272.04-12.61
-4.43%
Tesla

LPCN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LPCN has been loosely correlated with ZNTL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LPCN jumps, then ZNTL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LPCN
1D Price
Change %
LPCN100%
+1.99%
ZNTL - LPCN
37%
Loosely correlated
-2.60%
FGHQF - LPCN
28%
Poorly correlated
N/A
SCPX - LPCN
25%
Poorly correlated
-5.82%
PBYI - LPCN
23%
Poorly correlated
+1.19%
MIRM - LPCN
23%
Poorly correlated
-1.67%
More